Zimmer Biomet (ZBH) is higher in Thursday trading as investors continue to digest the company’s first-quarter 2026 results released April 28, 2026, with the focus on better-than-expected profitability and management’s decision to raise full-year adjusted EPS and free-cash-flow expectations. The move looks like a continuation of a post-earnings reversal after the stock sold off sharply immediately following the report, as the market re-anchors on the improved full-year outlook.

Zimmer Biomet reported first-quarter net sales of $2.087 billion, up 9.3% year over year, and adjusted diluted EPS of $2.09, up 15.5%. Management highlighted healthy end markets and momentum from recently launched products, and said it is raising adjusted EPS guidance and free-cash-flow expectations for 2026; the company’s earnings materials show updated 2026 adjusted EPS guidance of $8.40–$8.55. The numbers and the guidance increase are the main fresh catalysts being repriced as investors weigh whether the improved profitability can persist through the year.

After the initial reaction to the quarter, the next leg for ZBH will likely depend on evidence that improved execution translates into sustained margins and cash generation, not just a single-quarter beat. Traders will watch upcoming management commentary, follow-on analyst revisions, and any updates tied to the company’s go-to-market transformation progress—alongside routine demand signals for elective procedures that typically influence orthopedic names.